According to the 13th Gallen International Breast Cancer Conference (2013) Expert panel [41], endocrine therapy with tamoxifen is the most important intervention for the treatment of Luminal A breast cancer with ER-positive, PR-positive, HER2-negative status and the low expression of Ki67. The gene discussed is PGR; the disease is luminal A breast carcinoma.